BioCentury | Jun 30, 2016
Distillery Therapeutics

Therapeutics: Nuclear factor of activated T cells cytoplasmic calcineurin-dependent 1 (NFATc1); interleukin-10 (IL-10)

...suggest inhibiting NFATc1 could help treat psoriasis. In a mouse model of psoriasis, knockout of NFATc1...
...NFATc1 expression. Next steps could include testing NFATc1 inhibition in other models of psoriasis. TARGET/MARKER/PATHWAY: Nuclear factor of activated T cells cytoplasmic calcineurin-dependent 1 (NFATc1)...
BioCentury | Apr 14, 2016
Distillery Therapeutics

Therapeutics: Nuclear factor of activated T cells cytoplasmic calcineurin-dependent 3 (NFATc3; NFAT4); protein phosphatase 3 regulatory subunit B α (PPP3R1)

Cancer INDICATION: Colorectal cancer Patient sample and mouse studies suggest inhibiting NFATc3 or PPP3R1 could help treat colorectal cancer (CRC). In CRC patients, NFATc3 nuclear activity in tumor cells correlated with poor survival and NFATc3...
BioCentury | Feb 18, 2016
Distillery Therapeutics

Therapeutics: Nuclear factor of activated T cells cytoplasmic calcineurin-dependent 3 (NFATc3; NFAT4)

Inflammation INDICATION: Shock / trauma Rat studies suggest inhibiting NFATc3 could help treat traumatic brain injury (TBI). In a rat model of TBI, NFATc3 and astrocytes co-localized in the hippocampus seven days post-injury. In hippocampal...
BioCentury | May 21, 2015
Targets & Mechanisms

Intersection in marrow

...transmit RANKL signals in lipid rafts and decreased the translocation of the downstream transcription factor NFATc1...
...IGF-1 - Insulin-like growth factor-1 M-CSF (CSF1) - Macrophage colony-stimulating factor 1 NFATc1 - Nuclear factor of activated T cells cytoplasmic calcineurin-dependent 1...
BioCentury | May 8, 2014
Distillery Therapeutics

Indication: Cancer

...studies suggest inhibiting NFATc1 could help treat pancreatic cancers. In transgenic mice expressing proinflammatory, mutant NFATc1...
...in mice expressing only one of the two mutant genes. In Kras-mutant mice, inhibition of NFATc1...
...of neoplastic transformation called acinar-to-ductal metaplasia. Next steps include identifying a strategy to specifically inhibit NFATc1...
BioCentury | Nov 29, 2012
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Nuclear factor of activated T cells cytoplasmic calcineurin-dependent (NFATc); calcineurin Mouse studies suggest astrocyte-specific delivery of the synthetic peptide VIVIT could help...
BioCentury | Aug 26, 2010
Targets & Mechanisms

Metabolic origins for pulmonary hypertension

Researchers at the University of Alberta and Metabolic Modulators Research Ltd. have shown that a pathological shift toward glycolysis could be responsible for the deleterious vascular remodeling seen in pulmonary arterial hypertension. 1 The findings...
BioCentury | Jul 29, 2010
Distillery Therapeutics

Indication: Cancer

...leukemia (ALL) Calcineurin Aa (PPP3CA; CNA1); nuclear factor of activated T cells cytoplasmic calcineurin-dependent 1 (NFATc1) In vitro and mouse studies suggest that inhibiting CNA1-NFATc1...
...In CML cell lines and bone marrow samples from CML patients, a combination of the CNA1-NFATc1...
BioCentury | Jun 17, 2010
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology; nerve damage Glycogen dependent kinase 3 (GSK3); nuclear factor of activated T cells cytoplasmic calcineurin-dependent 3 (NFATC3; NFAT4); NFATC4 (NFAT3) A study in mice...
BioCentury | Feb 25, 2010
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Calcineurin (PPP3CA; PPP2B); nuclear factor of activated T cells cytoplasmic calcineurin-dependent 4 (NFATC4; NFAT3) In vitro and mouse studies suggest that inhibiting...
Items per page:
1 - 10 of 15